Population structure and antimicrobial resistance patterns of Salmonella Typhi isolates in urban Dhaka, Bangladesh from 2004 to 2016.
Anti-Bacterial Agents
/ pharmacology
Bangladesh
/ epidemiology
DNA, Bacterial
/ genetics
Drug Resistance, Bacterial
/ genetics
Genome, Bacterial
Genotype
Humans
Internationality
Polymorphism, Single Nucleotide
Retrospective Studies
Salmonella Infections
/ epidemiology
Salmonella typhi
/ drug effects
Time Factors
Travel
Urban Population
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
03
07
2019
accepted:
08
01
2020
revised:
10
03
2020
pubmed:
28
2
2020
medline:
28
4
2020
entrez:
28
2
2020
Statut:
epublish
Résumé
Multi-drug resistant typhoid fever remains an enormous public health threat in low and middle-income countries. However, we still lack a detailed understanding of the epidemiology and genomics of S. Typhi in many regions. Here we have undertaken a detailed genomic analysis of typhoid in urban Dhaka, Bangladesh to unravel the population structure and antimicrobial resistance patterns in S. Typhi isolated between 2004-2016. Whole genome sequencing of 202 S. Typhi isolates obtained from three study locations in urban Dhaka revealed a diverse range of S. Typhi genotypes and AMR profiles. The bacterial population within Dhaka were relatively homogenous with little stratification between different healthcare facilities or age groups. We also observed evidence of exchange of Bangladeshi genotypes with neighboring South Asian countries (India, Pakistan and Nepal) suggesting these are circulating throughout the region. This analysis revealed a decline in H58 (genotype 4.3.1) isolates from 2011 onwards, coinciding with a rise in a diverse range of non-H58 genotypes and a simultaneous rise in isolates with reduced susceptibility to fluoroquinolones, potentially reflecting a change in treatment practices. We identified a novel S. Typhi genotype, subclade 3.3.2 (previously defined only to clade level, 3.3), which formed two localized clusters (3.3.2.Bd1 and 3.3.2.Bd2) associated with different mutations in the Quinolone Resistance Determining Region (QRDR) of gene gyrA. Our analysis of S. Typhi isolates from urban Dhaka, Bangladesh isolated over a twelve year period identified a diverse range of AMR profiles and genotypes. The observed increase in non-H58 genotypes associated with reduced fluoroquinolone susceptibility may reflect a change in treatment practice in this region and highlights the importance of continued molecular surveillance to monitor the ongoing evolution of AMR in Dhaka. We have defined new genotypes and lineages of Bangladeshi S. Typhi which will facilitate the identification of these emerging AMR clones in future surveillance efforts.
Sections du résumé
BACKGROUND
Multi-drug resistant typhoid fever remains an enormous public health threat in low and middle-income countries. However, we still lack a detailed understanding of the epidemiology and genomics of S. Typhi in many regions. Here we have undertaken a detailed genomic analysis of typhoid in urban Dhaka, Bangladesh to unravel the population structure and antimicrobial resistance patterns in S. Typhi isolated between 2004-2016.
PRINCIPAL FINDINGS
Whole genome sequencing of 202 S. Typhi isolates obtained from three study locations in urban Dhaka revealed a diverse range of S. Typhi genotypes and AMR profiles. The bacterial population within Dhaka were relatively homogenous with little stratification between different healthcare facilities or age groups. We also observed evidence of exchange of Bangladeshi genotypes with neighboring South Asian countries (India, Pakistan and Nepal) suggesting these are circulating throughout the region. This analysis revealed a decline in H58 (genotype 4.3.1) isolates from 2011 onwards, coinciding with a rise in a diverse range of non-H58 genotypes and a simultaneous rise in isolates with reduced susceptibility to fluoroquinolones, potentially reflecting a change in treatment practices. We identified a novel S. Typhi genotype, subclade 3.3.2 (previously defined only to clade level, 3.3), which formed two localized clusters (3.3.2.Bd1 and 3.3.2.Bd2) associated with different mutations in the Quinolone Resistance Determining Region (QRDR) of gene gyrA.
SIGNIFICANCE
Our analysis of S. Typhi isolates from urban Dhaka, Bangladesh isolated over a twelve year period identified a diverse range of AMR profiles and genotypes. The observed increase in non-H58 genotypes associated with reduced fluoroquinolone susceptibility may reflect a change in treatment practice in this region and highlights the importance of continued molecular surveillance to monitor the ongoing evolution of AMR in Dhaka. We have defined new genotypes and lineages of Bangladeshi S. Typhi which will facilitate the identification of these emerging AMR clones in future surveillance efforts.
Identifiants
pubmed: 32106221
doi: 10.1371/journal.pntd.0008036
pii: PNTD-D-19-01039
pmc: PMC7064254
doi:
Substances chimiques
Anti-Bacterial Agents
0
DNA, Bacterial
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008036Subventions
Organisme : Wellcome Trust
ID : 098051
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106158/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106158
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Antimicrob Agents Chemother. 2014;58(1):212-20
pubmed: 24145532
Bioinformatics. 2010 Sep 15;26(18):2334-5
pubmed: 20624783
Infect Drug Resist. 2018 Nov 28;11:2491-2495
pubmed: 30555248
PLoS Negl Trop Dis. 2018 Apr 23;12(4):e0006408
pubmed: 29684021
Clin Infect Dis. 2018 Jun 1;66(12):1976-1977
pubmed: 29471386
Lancet Glob Health. 2014 Oct;2(10):e570-80
pubmed: 25304633
PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2316
pubmed: 23951368
Antimicrob Agents Chemother. 2009 Feb;53(2):716-27
pubmed: 19015365
PLoS Negl Trop Dis. 2015 Apr 24;9(4):e0003748
pubmed: 25909750
Bioinformatics. 2015 Oct 15;31(20):3350-2
pubmed: 26099265
Elife. 2016 Mar 11;5:e14003
pubmed: 26974227
mBio. 2018 Mar 20;9(2):
pubmed: 29559573
Clin Infect Dis. 2010 Jan 15;50(2):241-6
pubmed: 20014951
Epidemiol Infect. 2006 Apr;134(2):433-8
pubmed: 16490150
mBio. 2018 Nov 13;9(6):
pubmed: 30425150
N Engl J Med. 2002 Nov 28;347(22):1770-82
pubmed: 12456854
Genome Med. 2014 Nov 20;6(11):90
pubmed: 25422674
BMC Genomics. 2015 Sep 03;16:667
pubmed: 26336060
mBio. 2018 Feb 20;9(1):
pubmed: 29463654
Int J Infect Dis. 2010 Sep;14 Suppl 3:e93-9
pubmed: 20236850
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595
pubmed: 28594827
PLoS Negl Trop Dis. 2019 Sep 12;13(9):e0007620
pubmed: 31513580
PLoS Negl Trop Dis. 2016 Sep 22;10(9):e0004781
pubmed: 27657909
Clin Vaccine Immunol. 2009 Nov;16(11):1587-94
pubmed: 19741090
J Postgrad Med. 1989 Apr;35(2):79-82
pubmed: 2621666
Bioinformatics. 2011 Nov 1;27(21):2987-93
pubmed: 21903627
Nature. 2001 Oct 25;413(6858):848-52
pubmed: 11677608
Nat Commun. 2018 Nov 30;9(1):5094
pubmed: 30504848
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S74-S82
pubmed: 30845333
Antimicrob Agents Chemother. 2014 Jul;58(7):3895-903
pubmed: 24777092
Open Biol. 2011 Oct;1(2):110008
pubmed: 22645647
Lancet Infect Dis. 2019 Apr;19(4):369-381
pubmed: 30792131
PLoS Negl Trop Dis. 2011 Jul;5(7):e1245
pubmed: 21811646
Nat Genet. 2015 Jun;47(6):632-9
pubmed: 25961941
Bioinformatics. 2006 Nov 1;22(21):2688-90
pubmed: 16928733
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Commun. 2016 Oct 05;7:12827
pubmed: 27703135
Bioinformatics. 2004 Jan 22;20(2):289-90
pubmed: 14734327
Microb Genom. 2016 Nov 30;2(11):e000093
pubmed: 28348833
Science. 2011 Jan 28;331(6016):430-4
pubmed: 21273480
Nucleic Acids Res. 2015 Feb 18;43(3):e15
pubmed: 25414349